In order to prevent spam,
this email address cannot be copied.
Schizophrenia Research Forum: Researcher Profile - Gerard J. Marek
Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Profile Membership/Get Newsletter Log In Contact Us
 For Patients & Families
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
News
Research News
Conference News
Plain English
Forums
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
Interviews
Resources
What We Know
SchizophreniaGene
Animal Models
Drugs in Trials
Research Tools
Grants
Jobs
Conferences
Journals
Community Calendar
General Information
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
History
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by the Brain and Behavior Research Foundation and was created with funding from the U.S. National Institute of Mental Health.
Researcher Profile - Gerard J. Marek

RESEARCHER INFORMATION
First Name:Gerard J.
Last Name:Marek
Advanced Degrees:M.D., Ph.D.
Affiliation:Abbott Laboratories
Department:Neuroscience Development
Street Address 1:GPRD R48B AP4-1
Street Address 2:100 Abbott Park Road
City:Abbott Park
State/Province:IL
Zip/Postal Code:60064-6075
Country/Territory:U.S.A.
Phone:(847)937-4453
Fax:(847)937-0745
Email Address: gerard.marek@abbott.com
Disclosure:
(view policy) 
Member reports the following financial or other potential conflicts of interest: [Last Modified: 17 October 2008]

Work for Abbott Laboratories.
View all comments by Gerard J. Marek
Clinical Interests:
Drug abuse, Bipolar disorder , Schizophrenia, Depression, multiple sclerosis, Alzheimer's Disease
Research Focus:
Brain imaging, Clinical trials, Neurotransmission, Pharmacology, Electrophysiology, Glutamatergic transmission, Animal models
Work Sector(s):
Industry
Top Papers
Aghajanian, G.K. and Marek, G.J. Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacol., 36, 589-599, 1997.

Marek, G.J., Wright, R.A., Schoepp, D.D., Monn, J.A. and Aghajanian, G.K. Physiological antagonism between 5-hydroxytryptamine2A and group II metabotropic glutamate receptors in prefrontal cortex. J. Pharmacol. Exp. Ther., 292, 76-87, 2000.

Gewirtz, J.C. and Marek, G.J. Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors. Neuropsychopharmacol., 23, 569-576, 2000.


Marek, G.J., Wright, R.A., Gewirtz, J.C. and Schoepp, D.D. A major role for thalamocortical terminals in serotonergic hallucinogen receptor function in neocortex. Neurosci., 105, 379-392, 2001.



Marek, G.J., Wright, R.A. and Schoepp, D.D. 5-Hydroxytryptamine2A (5-HT2A) receptor regulation in rat prefrontal cortex: Interaction of a phenethylamine hallucinogen and the metabotropic glutamate2/3 receptor agonist LY354740. Neurosci. Lett., 403, 256-260, 2006.

Zhang, C. and Marek, G.J. Group III metabotropic glutamate receptor agonists selectively suppress excitatory synaptic currents in the rat prefrontal cortex induced by 5-hydroxytryptamine2A receptor activation. J. Pharmacol. Exp. Ther., 320, 437-447, 2007.


Rorick-Kehn, L.M., Johnson, B.G., Burkey, J.L., Wright, R.A., Calligaro, D.O., Marek, G.J., Nisenbaum, E.S., Catlow, J.T., Kingston, A.E., Giera, D.D., Herin, M.F., Monn, J.A., McKinzie, D.L. and Schoepp, D.D. Pharmacological and pharmacokinetic properties of a structurally-novel, potent, selective mGlu2/3 receptor agonist: In vitro characterization of Agonist (-)-(1R,4S,5S,6S)-4-Amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic Acid (LY404039). J. Pharmacol. Exp. Ther., 321, 308-317, 2007.

Zhang, C. and Marek, G.J., AMPA receptor involvement in 5-hydroxytryptamine2A receptor mediated prefrontal cortical excitatory synaptic currents and DOI-induced head shakes. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 32, 62-71, 2008.

Marek, G.J., Regulation of rat cortical 5-hydroxytryptamine2A-receptor mediated electrophysiological responses by repeated daily treatment with electroconvulsive shock or imipramine. Eur. Neuropsychopharmacol., 18: 498-507, 2008

Ardayfio, P.A., Benvenga, M.J., Chaney, S.F., Love, P.L., Catlow, Swanson, S.P. and Marek, G.J., The 5-hydroxytryptamine2A receptor antagonist R-(+)-a-(2,3-Dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl-4-piperidinemethanol (M100907) attenuates impulsivity after both drug induced impairment (dizocilpine) and enhancement (antidepressant drugs) of Differential-Reinforcement-of Low Rate 72-s behavior in the rat, J. Pharmacol. Exp. Ther., in press, 2008, doi:10.1124/jpet.108.143370.



Research Participants
Collaborators
Copyright © 2005- 2014 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright